Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: $LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lineage Cell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lineage Cell Therapeutics's position in the market.
Lineage Cell Therapeutics, Inc. presented 24-month visual acuity results of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The data showed BCVA gains of +5.5 letters at 24 months in Cohort 4 patients, with additional gains observed in patients with extensive OpRegen bleb coverage. The study suggested that OpRegen may counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with effects lasting at least 2 years post-administration.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) will announce its first quarter 2024 financial results on May 9, 2024. The company, focused on developing allogeneic cell therapies, will host a conference call to discuss the results and provide a business update.
Lineage Cell Therapeutics, Inc. (LCTX) received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) to support the 2nd Annual Spinal Cord Injury Investor Symposium. The symposium aims to accelerate development in spinal cord injury research and treatments by bringing together stakeholders in the field. It will focus on discussing current and future treatment alternatives, raising investor awareness, and broadening investment into spinal cord injury. The event will feature speakers from various organizations and will take place on June 26 and 27, 2024, in La Jolla, CA.
Lineage Cell Therapeutics, Inc. announces the passing of its Chairman, Mr. Alfred D. Kingsley, and appoints Michael H. Mulroy, J.D., as the new Chairman of the Board of Directors. Mr. Kingsley's significant contributions to the company are acknowledged, and Mr. Mulroy brings extensive experience in biotech and biopharma to his new role.
